[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

April 2018 | | ID: RFCAF52FA2BEN
La Merie Publishing

US$ 3,505.00 US$ 5,257.00 -33 %

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of effective cancer therapeutics. Both treatment modalities have in common that they are directed to intracellular targets wich are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy. While TCR engineered T-cells exert their effector function via the cytotoxicity of T-cells, antibodies can act via their intrinsic effects (ADCC, CDC) or by enhancing them as antibody-drug conjugates or T-cell redirecting bispecific antibodies.

This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy of cancer.

The original reports were published in January and May 2018, respectively:Detailed report descriptions, tables of contents and sample pages from the reports can be found on the respective product page.


More Publications